Termination of early human pregnancy with epostane.
Fifty-six healthy women, with a gestational length of less than 49 days from the last menstrual period, who requested termination of pregnancy were treated with Epostane, a progesterone synthesis inhibitor. Epostane, which competitively inhibits the 3 beta-hydroxy steroid dehydrogenase enzyme system, was given in the dose 200 mg X 4 for seven days. Physical examination, routine laboratory screening and determination of hCG, progesterone, estradiol and cortisol was performed on days 0, 7 and 14. The treatment resulted in 84% complete abortions (90% among women completing therapy). Two women experienced vaginal bleeding only, while 7 were non-responders. Among subjective side effects nausea dominated totally and was also the reason for discontinuation in 4 cases. The average length of bleeding among women with complete abortions was 10.7 days and the decrease in hemoglobin and hematocrit was very slight. Routine laboratory values remained within the normal range. Cortisol levels were elevated on day 7 compared to days 0 and 14, but all single values were within the normal limits.
D000005:Abdomen; D000028:Abortion, Induced; D000328:Adult; D000737:Androstenols / Q000009:adverse effects; D006063:Chorionic Gonadotropin / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D014592:Uterine Hemorrhage / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D000737:Androstenols; D006063:Chorionic Gonadotropin; D011374:Progesterone; D004958:Estradiol; C046855:epostane; D006854:Hydrocortisone